Q1 FY27 results: revenue up 35 percent, PAT triples; Philippines JV; promoter warrants

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

BALPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹90.03

prior close

₹88.25

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-2.4% vs market

Pharmaceuticals peers, median of 166sector+0.1%-2.4% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.3

15m

-0.3

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3+0.2-2.4+0.1-2.4

Next day

-3.1+0.2-3.3-0.2-2.9

-5.6+0.4-5.9-0.2-5.4

-5.0+0.7-5.8-0.1-4.9

-5.4+0.1-5.6-1.4-4.0

-4.6+0.7-5.2-0.8-3.8

-5.6+1.2-6.8-0.5-5.1

15d

-1.5+0.7-2.2+0.3-1.8

+19.4-1.2+20.6-0.2+19.6

+8.9-1.1+10.0-2.4+11.3

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bal Pharma Q1 FY27 standalone revenue grew to Rs 8,842.73 lakhs versus Rs 6,563.51 lakhs YoY, a 35 percent rise. Net profit jumped to Rs 116.10 lakhs from Rs 32.31 lakhs. Board approved a 65 percent stake JV in the Philippines with up to Rs 9 Cr investment, and allotted 10 lakh warrants at Rs 84 to promoter Shailesh Siroya, raising Rs 8.4 Cr (25 percent received). Auditors issued unmodified opinion.

Likely market impact

Strong top-line and profit growth signal operational momentum. Philippines JV expands ASEAN footprint. Promoter warrant allotment is a small dilution risk.